| Heading: |
Life Sciences: Venture Capital |
| Question ID: |
1814500 |
| UIN: |
61138 |
| House: |
Commons |
| Date tabled: |
2025-06-19 |
| Asking Member ID: |
4051 |
| Asking Member display name: |
John Glen
|
| Asking Member handle: |
JohnGlenUK
|
| Asking Member Twitter reference: |
@JohnGlenUK
|
| Member interest: |
false |
| Question text: |
To ask the Chancellor of the Exchequer, with reference to the British Business Bank's publication Small Business Equity Tracker 2024, if she will make a comparative assessment of (a) venture capital investment in the life sciences in the UK and the US and |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-27 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4077 |
| Answering Member display name: |
Emma Reynolds
|
| Answering Member handle: |
emmaforwycombe
|
| Answering Member Twitter reference: |
@emmaforwycombe
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The UK remains Europe’s leading destination for life sciences venture capital (VC) investment, according to the British Business Bank’s Small Business Equity Tracker 2024. The US market is larger in scale, supporting late-stage growth with deeper capital ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
14 |
| Answering body name: |
Treasury |
| Tweeted: |
true |